iNtRON Biotechnology, Inc.

Equities

A048530

KR7048530000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
6,520 ^KRW	-0.31%		-5.78%	-25.74%

03-13	INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-15	Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer	CI

INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 13, 2024 at 04:07 am

iNtRON Biotechnology, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 0.87918 million compared to KRW 1.37 million a year ago. Net loss was KRW 9,695.41 million compared to net income of KRW 5,711.91 million a year ago.

Basic loss per share from continuing operations was KRW 292 compared to basic earnings per share from continuing operations of KRW 168 a year ago. Basic loss per share was KRW 292 compared to basic earnings per share of KRW 168 a year ago.

Latest news about iNtRON Biotechnology, Inc.

INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer	02-14	CI
INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON	23-10-31	MT
INtRON Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	23-08-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	23-08-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	23-08-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	23-08-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	23-08-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	23-08-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	23-08-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	23-08-03	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with 324,118 shares, representing 0.97% for KRW 2,997.54 million.	23-08-02	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with	23-08-02	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on September 20, 2022, has expired with 294,186 shares, representing 0.87% for KRW 2,998.6 million.	23-08-02	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	23-07-06	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	23-07-06	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	23-07-06	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	23-07-06	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on July 5, 2022, has expired with 274,732 shares, representing 0.81% for KRW 2,997.69 million.	23-07-04	CI
INtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome	23-05-29	CI
INtRON Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
INtRON Biotechnology, Inc. Confirms Cancer-Controlling Effect of Phageria Drug Candidate in the Organoid Model	23-04-03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	23-03-06	CI

Chart iNtRON Biotechnology, Inc.

Duration

Period

More charts

Company Profile

iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INTRON BIOTECHNOLOGY, INC.	-25.74%	159M
VERTEX PHARMACEUTICALS INCORPORATED	+7.68%	111B
REGENERON PHARMACEUTICALS, INC.	+11.16%	106B
BIONTECH SE	-12.27%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.61%	16.81B
SAREPTA THERAPEUTICS, INC.	+38.95%	12.54B
LEGEND BIOTECH CORPORATION	-24.43%	8.09B

Bio Therapeutic Drugs